Review ArticlesThe Partnership for Accelerating Cancer TherapiesBaker, Rebecca G. PhD*; Hoos, Axel X. MD, PhD†; Adam, Stacey J. PhD‡; Wholley, David M.Phil‡; Doroshow, James H. MD§; Lowy, Douglas R. MD§; Tabak, Lawrence A. DDS, PhD*; Collins, Francis S. MD, PhD*Author Information From the *National Institutes of Health, Bethesda, MD; †GlaxoSmithKline, Collegeville, PA; ‡Foundation for the National Institutes of Health, North Bethesda; and §National Cancer Institute, Bethesda, MD. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Rebecca Baker, PhD, National Institutes of Health, Bldg. 1, 1 Center Dr, Bethesda, MD 20892. E-mail: [email protected]. The Cancer Journal: 5/6 2018 - Volume 24 - Issue 3 - p 111-114 doi: 10.1097/PPO.0000000000000321 Buy Metrics Abstract As a part of the Cancer Moonshot, the National Cancer Institute, part of the National Institutes of Health, the Foundation for National Institutes of Health, the US Food and Drug Administration, and 12 pharmaceutical companies have formed a 5-year, $220 million precompetitive public-private research collaboration called the Partnership for Accelerating Cancer Therapies. A systematic cross-sector effort to identify and develop robust, standardized biomarkers and related clinical data, Partnership for Accelerating Cancer Therapies will support the selection and testing of promising immunotherapies for the treatment of cancer, with the goal of bringing effective therapy to more patients. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.